Overview
Quick answer
Retatrutide is not approved anywhere in the world, including Australia. It is not on the Australian Register of Therapeutic Goods, and the TGA names it as an example of an unapproved peptide product.
The weight-loss figures you have seen come from company announcements rather than published trials. The one published phase 3 trial studied type 2 diabetes, not obesity.
Overview
Key takeaways
Retatrutide is a single investigational molecule that acts on three receptors at once: GIP, GLP-1 and glucagon.
The registered medicines it gets compared with act on one or two of those receptors, and not on the glucagon receptor.
Retatrutide is not approved by any medicines regulator anywhere in the world.
It is not on the Australian Register of Therapeutic Goods, so it is not an approved medicine here.
The TGA names retatrutide as an example of an unapproved peptide product.
It does not appear in the Poisons Standard, which is not the same thing as being unregulated.
Four retatrutide trials are peer reviewed and published, and the large obesity results are not among them.
The single published phase 3 trial studied type 2 diabetes rather than obesity.
Liver fat in the published trials was measured by MRI scan, not by any blood test.
Whether retatrutide is prohibited in sport is genuinely unclear, so athletes should ask Sport Integrity Australia.
Basics
What Retatrutide is and what it acts on
Retatrutide is an investigational molecule developed by Eli Lilly, also known as LY-3437943. The published trials describe it as a single agonist of three receptors at once: GIP, GLP-1 and glucagon. Registered medicines in this family act on one or two.
Investigational means it is still being studied. It is not a medicine you can be prescribed in Australia, and the company itself states it cannot be legally sold or marketed for human use.
Almost every article about retatrutide names those three receptors and then moves on without saying what any of them do. They are worth a paragraph each, because what the molecule acts on is what the unpublished trials were built to measure.
What "agonist" means
An agonist is a molecule that switches a receptor on, standing in for the hormone that normally does it. A triple agonist switches on three. It is not three medicines combined. It is one molecule shaped to fit three different receptors, which is why the published trials describe a single substance rather than a combination.
The GLP-1 receptor
GLP-1 is glucagon-like peptide-1, a hormone the gut releases in response to food. Australian general practice guidance lists its effects as stimulating insulin secretion, reducing glucagon secretion and the glucose the liver makes itself, slowing gastric emptying, and promoting satiety so a person eats less. This is the receptor every registered medicine in this family acts on.
The GIP receptor
GIP is glucose-dependent insulinotropic polypeptide, the other main incretin hormone released by the gut when you eat. Australian product information for the registered GIP and GLP-1 medicine states that both receptors are found in areas of the brain important for appetite regulation, and that GIP receptors are also present on adipocytes, the body’s fat cells.
The glucagon receptor
This is the third one, and it is the one neither semaglutide nor tirzepatide acts on. Published mechanism work on a different glucagon and GLP-1 molecule describes glucagon receptor activation in the liver as raising energy expenditure, which is a different lever from eating less. What it contributes in people taking retatrutide is exactly what the unpublished obesity trials were designed to establish.
That point is worth sitting with. The company with the strongest commercial reason to say otherwise is the one stating it cannot be legally sold or marketed for human use.
Approval
Approved nowhere, not just not here
A lot of coverage implies retatrutide is available somewhere and simply has not reached Australia yet. That is not the position.
Not approved in Australia
A search of the Australian Register of Therapeutic Goods returns no matching results for retatrutide. The same search returns dozens of registered products for semaglutide and tirzepatide. Retatrutide is not an approved medicine in Australia.
Not approved in the United States
Retatrutide has no entry in the United States Food and Drug Administration approved drug records. Eli Lilly has said it plans to submit retatrutide for United States approval in the first quarter of 2027. A plan to submit is not a submission, and a submission is not an approval.
Not approved in the European Union
Retatrutide does not appear in the European Union register of authorised human medicines. Semaglutide and tirzepatide both do.
Phase 3 finishing is not approval
Completing phase 3 trials means a company has the evidence it intends to submit. Regulators then assess it, which takes time and can end in refusal or a narrower indication than the company sought. Coverage that treats phase 3 results as approval skips that entire step.
The obvious question
Being sold is not the same as being approved
If you have already searched for this, sellers were probably the first thing you saw. Here is how that fits with everything above.
Search for retatrutide and you will find sellers, some of them presenting as Australian. That does not contradict anything above. Being sold is not the same as being approved, and the gap between those two things is the whole subject of this page.
Approval is an assessment. A regulator examines how a product is made, what it contains, what it does and what it risks, and then decides. Nothing sold outside that process has been through it, so nothing is known about a particular vial beyond what its label claims.
The TGA has stated that a "research use only" label does not make supply lawful, and that poorly labelled products will not be released at the border. The Australian Border Force seizes and destroys non-compliant imports.
Labels can also simply be wrong. When the TGA laboratory-tested a set of imported weight-loss products, several contained no GLP-1 of any kind. That testing covered different products, but it shows what unapproved goods can turn out to be.
The TGA has reported liver damage and hospitalisations associated with unapproved peptide products as a group. Whether any particular transaction is lawful is not a question this page answers: state and territory laws add further controls, and the TGA and Australian Border Force are the authorities on it.
Australian context
Where it sits in Australian law
Not on the ARTG
The Australian Register of Therapeutic Goods, usually shortened to the ARTG, is the list of products the TGA has assessed for quality, safety and performance and allowed to be supplied here. Retatrutide has not been assessed, so nothing about its manufacture, strength or contents has been checked by an Australian regulator.
Not in the Poisons Standard
The Poisons Standard is the legislative instrument that sets how tightly each substance is controlled in Australia, from open sale through to prohibition. Retatrutide has no entry in the current one, the June 2026 instrument. Semaglutide and tirzepatide are both listed there as Schedule 4, meaning prescription only. Retatrutide has no schedule at all.
Unscheduled does not mean unregulated
This is the point most often got wrong. The TGA states that peptide products are regulated as therapeutic goods under the Therapeutic Goods Act 1989. The absence of a Poisons Standard entry is not permission, and it is not a gap someone has found.
Named by the TGA
In April 2026 the TGA published guidance on unapproved peptide products naming retatrutide alongside BPC-157, GHK-Cu, TB-500 and CJC-1295. A June 2026 media release repeated that list and reported hospitalisations associated with unapproved peptide products as a group.
Importing for personal use
The Personal Importation Scheme allows individuals to import some goods that are not on the ARTG, subject to conditions covering labelling, quantity, personal use, and holding an Australian prescription where a medicine is prescription only here. Whether retatrutide meets those conditions is not a question this page can answer. The TGA and the Australian Border Force are the authorities on it, and the TGA has said that a "research use only" label does not make supply lawful.
Evidence
Published results and company announcements
These are two different things, and almost all coverage blends them.
Peer reviewed and published
- Phase 2 trial in obesity, New England Journal of Medicine, August 2023, 338 participants over 48 weeks.
- Phase 2 trial in type 2 diabetes, The Lancet, August 2023, 281 participants over 36 weeks.
- Phase 2a liver-fat substudy, Nature Medicine, July 2024, 98 participants.
- Phase 3 trial in type 2 diabetes (TRANSCEND-T2D-1), The Lancet, June 2026, 537 participants over 40 weeks.
Announced by the company, not yet published
- TRIUMPH-4, announced December 2025, 445 participants over 68 weeks.
- TRIUMPH-1, announced May 2026, 2,339 participants over 80 weeks.
- TRIUMPH-2, announced July 2026, 1,152 participants over 80 weeks.
- TRIUMPH-3, announced July 2026, 1,949 participants over 80 weeks.
Every large weight-loss figure circulating for retatrutide comes from the second list. Eli Lilly has said those results will be presented at medical meetings and published in peer-reviewed journals in future, which is a plain statement that they have not been yet.
A company topline is a summary the sponsor chooses to release before independent review. The headline number is usually accurate. What is missing is the full safety picture, the analysis choices, and the detail a clinician needs to judge whether a result applies to a particular person.
This matters for a reader more than it might appear. The single published phase 3 trial studied blood-glucose control in type 2 diabetes. The obesity trials everyone is quoting have not been through peer review.
Testing
What the trials actually measured
Worth knowing before assuming a blood panel reproduces any of it.
Body weight and HbA1c
Body weight was the primary measure in the obesity trials and HbA1c in the diabetes trials. Both were recorded under a study protocol with scheduled visits.
Liver fat by MRI
The published liver substudy enrolled 98 people from the obesity trial who already had a liver fat content of 10 per cent or more, measured by MRI-PDFF, or magnetic resonance imaging proton density fat fraction, which reports what proportion of the liver is fat. Across the trial arms, mean relative liver fat fell 42.9 to 82.4 per cent at 24 weeks against a 0.3 per cent rise on placebo, and 27 to 86 per cent of participants reached a liver fat content under 5 per cent against none on placebo. Every one of those figures came from a scanner. No blood test was used, and this is the clearest example of a trial endpoint that no blood panel reproduces.
Liver enzymes and fibrosis markers
ALT, AST and fibrosis indices were measured in that substudy alongside the imaging. They were supporting measures, not the endpoint the trial was designed around.
Cardiometabolic secondary measures
Triglycerides, non-HDL cholesterol, hs-CRP, systolic blood pressure and waist circumference were reported as secondary measures. Secondary measures describe an average across a study group and are not a monitoring schedule for a person.
Measures reported across the trials
- Body weight
- HbA1c
- Liver fat by MRI-PDFF, which is an imaging measure rather than a blood test
- ALT and AST, in the liver substudy only
- Triglycerides and non-HDL cholesterol
- hs-CRP
- Systolic blood pressure
Safety
What the side effects were in the trials
If you are reading this because you are considering it, this is probably the section you came for, so here is what the published trials actually reported.
One caveat first, and it matters. The trial below enrolled 338 adults over 48 weeks. It is a phase 2 study, which is not the scale on which safety questions get settled.
Gastrointestinal effects were the most common
The published phase 2 obesity trial reported gastrointestinal events as the most common adverse events in the retatrutide groups. It described them as related to the amount given, mostly mild to moderate in severity, and partially reduced by starting at a lower amount rather than a higher one.
Heart rate rose, then came back down
The same trial reported increases in heart rate that tracked the amount given, peaked at 24 weeks, and declined after that. A rise that reverses is a different thing from one that persists, and it is the kind of detail that only appears in a published paper rather than in an announcement.
Everything above happened under supervision
Each of those findings describes people in a trial: screened for eligibility, given a product of known identity and strength, seen at scheduled visits, and monitored by clinicians who could act. None of those conditions holds for anything obtained outside that setting, which makes the numbers a poor guide to what happens outside it.
The safety data everyone is relying on is the unpublished part
The large obesity trials, TRIUMPH-1 through TRIUMPH-4, are where the widely quoted weight-loss figures come from, and none of them has been published. That means the full safety picture at that scale, across thousands of participants, is precisely the part that has not been through peer review. The headline travels; the safety detail has not.
That last point is the honest summary of this section. The most-quoted results and the least-available safety data are the same trials.
Testing
What testing cannot tell you, and what does
Each limit below is followed by what would actually settle the question.
Questions no blood panel answers here
- Whether a product actually contains retatrutide. Testing a person does not test a product, and unapproved goods have not been assessed for identity, strength or purity. Only laboratory analysis of the product itself answers that, which is the kind of testing the TGA runs on imported goods.
- Whether liver fat has changed. MRI-PDFF scanning is what answers it, and that is an imaging appointment rather than a pathology request. The published trials used it precisely because no blood measure substitutes for it.
- Whether the substance is working in the sense the trials measured. Nothing outside a trial answers it, because what those endpoints measure is a difference against a placebo group assessed the same way at the same scheduled visits, some of it independently adjudicated.
- Whether use is safe for a particular person. Nothing published answers it. Establishing that is the work of the regulatory assessment no authority anywhere has completed, and no published trial validates any consumer blood panel as safety monitoring here.
- Whether an adverse effect came from the substance, from something else in an unapproved product, or from an unrelated condition. Attribution needs a known product and a clinical assessment, and no blood result answers it on its own.
What markers do mean, if that is what brought you here
- Blood tests on GLP-1 and GIP medicines in AustraliaThe same questions asked about the medicines in this family that Australia has actually registered, including what their product information says about laboratory tests.
- Fasting insulin test AustraliaOne of the earliest markers to move in metabolic health, and a worked example of a result that is often normal while something is already changing.
- HOMA-IR AustraliaCalculated from fasting glucose and insulin on the same draw. A short lesson in why one number rarely means anything without another beside it.
- Preventative blood test AustraliaWhat a general preventative panel in Australia contains, and what Medicare does and does not fund for someone without symptoms.
Sport
Sport and anti-doping
Two official sources point in different directions. Both are quoted here rather than resolved.
Sport Integrity Australia publishes a page on retatrutide which states that it is not listed on the Prohibited List, and that GLP-1 agonists are currently not prohibited in sport.
The WADA 2026 Prohibited List does not name retatrutide either. Its category S0 covers any pharmacological substance with no current approval by any government regulatory health authority for human therapeutic use, is prohibited at all times, and gives substances in clinical development as an example. S0 names BPC-157, which shows the category is applied to unapproved peptides it does not individually list.
Those two facts sit awkwardly together and this page will not pretend to resolve them. Anti-doping operates on strict liability, which means an athlete is responsible for whatever is found in their sample regardless of how it got there or whether they intended it. An athlete who relies on "not listed" and is later assessed under S0 carries the consequence anyway. Contact Sport Integrity Australia before using anything in this category.
FAQ
Frequently asked questions
- What does retatrutide do in the body?
- It acts on three receptors at once. Published trials describe it as an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. The first two are the incretin pathways the registered medicines in this family use, affecting insulin, glucagon, stomach emptying and appetite. The glucagon receptor is the addition, and what it contributes in people is what the unpublished obesity trials were designed to measure.
- Is retatrutide approved in Australia?
- No. It is not on the Australian Register of Therapeutic Goods, so it is not an approved medicine in Australia. It is also not approved in the United States or the European Union. As at August 2026 no medicines regulator anywhere has approved it.
- What is the TGA status of retatrutide?
- The TGA names retatrutide as an example of an unapproved peptide product, in guidance published in April 2026 and a media release in June 2026. It is not registered on the ARTG and it does not appear in the Poisons Standard.
- Why can I find retatrutide for sale if it is not approved?
- Because being sold and being approved are different things. Approval means a regulator has assessed how a product is made and what it contains, and no regulator anywhere has done that for retatrutide. Anything offered outside that process has not been through it, and the TGA has said a "research use only" label does not make supply lawful.
- Is retatrutide legal in Australia?
- This page cannot answer that, and a page giving you a confident yes or no is worth treating with suspicion. Peptide products are regulated as therapeutic goods under the Therapeutic Goods Act 1989, the Personal Importation Scheme has conditions attached, and the TGA and Australian Border Force are the authorities on how those apply.
- What phase is retatrutide in, and are the weight loss results published?
- Phase 3 trials have reported results, and one has been published in a peer-reviewed journal, in type 2 diabetes. The large obesity results have not: TRIUMPH-1 through TRIUMPH-4 exist as company announcements and conference presentations, and Eli Lilly has said detailed results will be published in future. Completing phase 3 is not approval, and Lilly plans to submit for United States approval in the first quarter of 2027.
- What are the side effects of retatrutide?
- The published phase 2 obesity trial reported gastrointestinal effects as the most common, related to the amount given, mostly mild to moderate, and partly reduced by starting lower. It also reported increases in heart rate that peaked at 24 weeks and declined after that. That trial enrolled 338 people. Safety data from the large obesity trials has not been published, so the fullest picture does not exist publicly.
- Is retatrutide banned in sport?
- Sport Integrity Australia states it is not listed on the Prohibited List. The WADA list does not name it either, but category S0 covers substances not approved by any regulator for human use. Athletes should contact Sport Integrity Australia rather than rely on either reading.
- What blood tests monitor retatrutide?
- None are established. The published trials measured markers under a study protocol, and liver fat was measured by MRI scan rather than by blood. No published trial validates a consumer blood panel as monitoring for this substance.
- Does Hemexa prescribe or supply retatrutide or other peptides?
- No. Hemexa does not prescribe, dispense, or supply any medicine or peptide. Hemexa is an Australian preventative blood-testing membership that helps people track their own results over time, and treatment decisions stay with your own doctor.
About this page
Who publishes this page
Hemexa is an Australian preventative blood-testing membership. What we do is turn repeat pathology into trends a person can read over time and take to their own doctor, which is why a page like this one keeps insisting on the difference between a measurement and a conclusion. It exists because the search results for retatrutide are dominated by sellers, and the accurate answer, that no regulator anywhere has approved it, is not the one being given.
What Hemexa is
- An Australian membership for preventative blood testing and tracking results over time
- A platform that turns repeat pathology into trends a person can discuss with their own doctor
- The publisher of this educational explainer
What Hemexa is not
- Not a prescriber. Hemexa does not prescribe any medicine or peptide.
- Not a pharmacy, and not a supplier of medicines or peptides.
- Not a clinic, and not a route to treatment or access.
How this page is maintained. Last reviewed 15 August 2026.
- Written by
- The Hemexa editorial team. A company publication, so no individual byline.
- Next review triggered by
- Publication of any TRIUMPH trial, a regulatory submission or approval in any country, a change to the Poisons Standard, or a Sport Integrity Australia or WADA update.
- Sources
- Every factual claim traces to a numbered primary source below: Australian regulators, the Poisons Standard, peer-reviewed journals, the manufacturer’s own statements, and anti-doping authorities. Where a regulator has since updated its advice, the regulator page is authoritative.
- Scope
- Regulatory status and evidence stage. This page does not recommend, supply, or help anyone obtain anything, and it gives no amounts or protocols.
Nothing here is medical advice. Read the health disclaimer, and take any question about your own treatment to your doctor.
Sources
References
Primary sources, with the date each was accessed. Where a regulator has updated its advice, the regulator page is authoritative over this summary.
Therapeutic Goods Administration. Australian Register of Therapeutic Goods search. Searched for retatrutide, no matching results, 15 August 2026. Accessed 15 August 2026.
Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Published 13 April 2026. Accessed 15 August 2026.
Therapeutic Goods Administration. Concerns regarding public health risks associated with unapproved peptide products. Media release, 19 June 2026. Accessed 15 August 2026.
Therapeutic Goods Administration. Personal Importation Scheme. Last updated 19 January 2026. Accessed 15 August 2026.
Federal Register of Legislation. Therapeutic Goods (Poisons Standard, June 2026) Instrument 2026. Made 28 May 2026, in effect 1 June 2026, retatrutide does not appear. Accessed 15 August 2026.